SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT
申请人:Kim Ki Young
公开号:US20140024636A1
公开(公告)日:2014-01-23
Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), and is useful in the treatment of various diseases that are mediated by 11β-HSD1.
Synthesis and Biological Evaluation of Cyclic Sulfamide Derivatives as 11β-Hydroxysteroid Dehydrogenase 1 Inhibitors
作者:Se Hoan Kim、Ju Han Bok、Jae Hong Lee、Il Hyang Kim、Sung Wook Kwon、Gui Bin Lee、Seung Kyu Kang、Ji Seon Park、Won Hoon Jung、Hee Yeon Kim、Sang Dal Rhee、Sung Hoon Ahn、Myung Ae Bae、Deok Chan Ha、Ki Young Kim、Jin Hee Ahn
DOI:10.1021/ml200226x
日期:2012.2.9
A new series of cyclic sulfamidederivatives were synthesized and evaluated for their ability to inhibit 11beta-HSD1. Among this series, 18e showed good in vitro activity toward human 11beta-HSD1, selectivity against 11beta-HSD2, microsomal stability, and pharmacokinetic and safety profiles (hERG, CYP, and acute toxicity). Additionally, 18e exhibited good in vivo efficacy in rat and monkey models.
Hydrazine derivatives and their pharmaceutically acceptable salts useful for the treatment of inflammatory and autoimmune diseases, osteoarthritis, respiratory diseases, tumors, cachexia, cardiovascular disease, fever, hemorrhage, and sepsis.